Glypican 5 is an interferon-beta response gene: a replication study

Abstract

Background

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Interferon-beta is the most usual therapy in relapsing-remiting MS. However, approximately 50% of the treated patients do not respond adequately. Very recently, a genome-wide association study on interferon-beta pharmacogenetics has described polymorphisms at several genes that are associated with response to this treatment. Our aim is to replicate the results obtained at the two loci most strongly implicated in the response to interferon-beta treatment, HAPLN1 and GPC5.

Patients and methods

We performed a case–control study, analyzing 199 patients with MS treated with interferon-beta for at least 2 years and at least two documented relapses over the 2 years, previous to treatment onset. Responders had neither relapses nor increase in expanded disability status scale (EDSS) over the 2-year follow-up period, whereas nonresponders had at least two relapses or an increase in EDSS of at least 1 point. We studied three single-nucleotide polymorphisms (SNPs) in the GPC5 locus and three SNPs in the HAPLN1 locus by TaqMan technology. Allelic frequencies between responders and nonresponders were compared by a chi-square test.

Results

An association was found between GPC5 polymorphisms and the response to interferon-beta therapy in patients with MS, in agreement with earlier data (responder vs nonresponder patients: rs10492503, P = 0.0005). The other locus studied (HAPLN1) did not show association with treatment response to interferon-beta (all SNPs P > 0.05).

Conclusions

We confirm the association of polymorphisms within GPC5 with response to interferon-beta therapy in patients with MS.

Keywords

GPC5 HAPNL1 interferon-beta treatment multiple sclerosis

Get full access to this article

View all access options for this article.

References

1 Hafler DA Slavik JM Anderson DE O'Connor KC De Jager P Baecher-Allan C . Multiple sclerosis. Immunol Rev 2005; 204: 208–231.

2 Marrie RA . Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 2004; 3: 709–718.

3 Svejgaard A . The immunogenetics of multiple sclerosis. Immunogenetics 2008; 60: 275–286.

4 Hafler DA Compston A Sawcer S . Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851–862.

5 Weinstock-Guttman B Ramanathan M Zivadinov R . Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther 2008; 8: 1435–1447.

6 Markowitz CE . Interferon-beta: mechanism of action and dosing issues. Neurology 2007; 68: S8–S11.

7 Martinez A de las Heras V Mas Fontao A . An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. J Neuroimmunol 2006; 173: 196–199.

8 Byun E Caillier SJ Montalban X . Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337–344.

9 O'Doherty C Villoslada P Vandenbroeck K . Pharmacogenomics of type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev 2007; 18: 211–222.

10.

10 Leyva L Fernandez O Fedetz M . IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005; 163: 165–171.

11.

11 Poser CM Paty DW Scheinberg L . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

12.

12 Filmus J Capurro M Rast J . Glypicans. Genome Biol 2008; 9: 224.

13.

13 Jackson SM Nakato H Sugiura M . dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp. Development 1997; 124: 4113–4120.

14.

14 Baranzini, SE, Wang, J, Gibson, RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18(4)767–778.